Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Eurofins Scientific reports Q3 revenue growth, but warns of weaker organic growth in 2026

Eurofins Scientific increased group revenue in the third quarter by 6.1% to €1.91 billion and reported organic growth of 3.5%. Revenue in Europe rose 3.7% to €985 million, and in North America 7.9% to €712 million. For 2026 the company expects organic growth below its mid-single-digit target range, but aims to return to the targeted growth in 2027 and confirms an adjusted EBITDA margin of over 22.5%. The stock fell intraday after the more cautious outlook, but later reversed and again reached a 52-week high. » More on deraktionaer.de
Eurofins Scientific: €10,000 investment ten years ago would have grown to €18,888.59

Ten years ago the closing price of Eurofins Scientific shares was €37.43, meaning a €10,000 investment would have bought about 267.165 shares. At the closing price on 11 September 2026 of €70.70, that investment would be worth €18,888.59, an increase of 88.89 percent. Eurofins Scientific most recently reached a market capitalization of €12.27 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
Eurofins Scientific reports weak organic growth in first half

Eurofins Scientific recorded organic growth of 2.7% in the first half, below market expectations. Its biopharma business and CDMO activities showed weakness, while product testing remained stable. Revenue of €3.701 billion matched consensus; adjusted EBITDA of €877 million and a margin of 23.7% beat expectations. Adjusted earnings per share rose 25% to €1.64 and free cash flow improved significantly; the company confirms its full-year guidance with mid-single-digit organic growth and margin improvement. » More on de.investing.com
Eurofins Scientific misses Q1 revenue forecast, shares fall 11%

Eurofins Scientific reported Q1 2026 revenue of USD 1.79 billion, missing the USD 1.81 billion forecast, weighed down by extreme weather in North America and northern Europe and by currency headwinds. The stock fell about 11.1% after the announcement and approached its 52-week low. Management remains confident it will achieve mid-single-digit organic growth and the planned margin expansion for the year through operational efficiency measures. » More on de.investing.com
Eurofins: earnings per share up 24%, organic growth accelerates

Eurofins reported for fiscal 2025 an increase in adjusted earnings per share of 24% to €2.31, with revenue up 5% to €7,296m and organic growth of 4.1% (3.9% H1 vs. 4.4% H2). Adjusted EBITDA rose 6% to €1,641m with a margin of 22.5%; free cash flow improved 9% to €876m. The company highlighted operational efficiency, working-capital improvements and continued M&A activity; net debt stands at 2.2x. For 2026 Eurofins expects mid-single-digit organic growth, and it confirmed its 2027 targets of 6.5% annual organic growth and a 24% adjusted EBITDA margin; the stock fell about 5% on the day of the release. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eurofins Scientific has already paid €0.61 in dividends. The last payout was in April.

Financials

In the last quarter, Eurofins Scientific had revenue of €3.7bn and net profit of €302m

(EUR)	June 2026	YoY
Revenue	3.7bn	-
Gross profit	499m	-
Net profit	302m	-
EBITDA	797m	-

Fundamentals

Metric	Value
Market capitalization	€15.39bn
Number of shares	173.6m
52-week high/low	€89.28 - €54.86
Dividend yield	0.70%
Dividends TTM	€0.61
Beta	0.81
P/E ratio	29.55
PEG ratio	0.97
P/B ratio	4.30
P/S ratio	2.08

Company profile

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.